Fig S1. Individual changes in spleen size by palpation from BL to EOC6 for patients in (A) JAKARTA and (B) JAKARTA2 with platelet counts of 50 to <100 ×10⁹/l at study entry.

Changes from BL to EOC6 are plotted for patients with data available at both time points.

BL, baseline; EOC6, end of cycle 6.
Fig S2. Individual changes in MFSAF TSS changes from BL to EOC6 for patients in (A) JAKARTA and (B) JAKARTA2 with platelet counts of 50 to <100 ×10⁹/l at study entry. Changes from BL to EOC6 are plotted for patients with data available at both time points. BL, baseline; EOC6, end of cycle 6; MFSAF TSS, Myelofibrosis Symptom Assessment Form total symptom score.
Fig S3. Median changes from BL in TSS and in individual symptom scores on the modified MFSAF with fedratinib at EOC6 in patients in the combined JAKARTA and JAKARTA2 trials with platelet counts of 50 to <100 $\times 10^9$/l at study entry and who had available data at BL and at EOC6.

BL, baseline; EOC6, end of cycle 6; MFSAF, Myelofibrosis Symptom Assessment Form; TSS, total symptom score.
Fig S4. Changes in mean platelet counts over time for patients in JAKARTA and JAKARTA2.

BL, baseline; CxD1, cycle x day 1; EOC6, end of cycle 6; SE, standard error.